How Investors Are Reacting To Nektar Therapeutics (NKTR) Launching Global Phase 3 ZENITH AD Trials

• Nektar Therapeutics recently initiated the first two global registrational Phase 3 trials, ZENITH AD-1 and ZENITH AD-2, for rezpegaldesleukin in patients aged 12 and older with moderate-to-severe atopic dermatitis, following encouraging Phase 2b data and prior FDA Fast Track designations.
• This move advances a first-in-class T-reg–targeting biologic into pivotal testing across North America, Europe and Asia-Pacific, underscoring Nektar’s ambition to build a broad autoimmune and inflammatory disease franchise.
• Now we’ll examine how launching these large Phase 3 ZENITH AD trials for rezpegaldesleukin could reshape Nektar’s investment narrative and risk profile.

We've uncovered the 7 dividend fortresses yielding 5%+ that don't just survive market storms, but thrive in them.

Nektar Therapeutics Investment Narrative Recap

To own Nektar, you need to believe rezpegaldesleukin can successfully progress through late stage trials and ultimately support a viable autoimmune franchise, despite ongoing losses and reliance on equity funding. The launch of the large Phase 3 ZENITH AD trials heightens the importance of clinical execution as the key near term catalyst, while also amplifying the biggest current risk: that an expensive, multi year registrational program may strain cash without yet resolving approval or commercialization uncertainty.

The April 2026 Phase 2b REZOLVE AD maintenance data, which showed durable efficacy and a favorable safety profile through Week 52, is especially relevant alongside the ZENITH AD start. That earlier dataset underpins the chosen 24 micrograms per kilogram dosing and supports the decision to test both monthly and quarterly maintenance regimens at scale. Together, the Phase 2b results and the new Phase 3 trials frame rezpegaldesleukin as the centerpiece of Nektar’s near term catalyst path.

Yet while Phase 3 progress feels encouraging, investors should still be aware of...

Read the full narrative on Nektar Therapeutics (it's free!)

Nektar Therapeutics’ narrative projects $54.9 million revenue and $10.7 million earnings by 2029. This implies fairly flat yearly revenue growth and a $168.8 million earnings increase from -$158.1 million today.

Uncover how Nektar Therapeutics' forecasts yield a $153.25 fair value, a 121% upside to its current price.

Exploring Other Perspectives

Some bullish analysts were already modeling about US$136,000,000 of 2029 revenue and a swing to US$26,800,000 in earnings, which is far more optimistic than the consensus and could be tested by how the new ZENITH AD data evolve against concerns about persistent losses and dilution risk.

Explore 3 other fair value estimates on Nektar Therapeutics - why the stock might be worth over 2x more than the current price!

Reach Your Own Conclusion

Don't just follow the ticker - dig into the data and build a conviction that's truly your own.

• A great starting point for your Nektar Therapeutics research is our analysis highlighting 1 key reward and 3 important warning signs that could impact your investment decision.
• Our free Nektar Therapeutics research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Nektar Therapeutics' overall financial health at a glance.

Curious About Other Options?

Markets shift fast. These stocks won't stay hidden for long. Get the list while it matters:

• Uncover the next big thing with 21 elite penny stocks that balance risk and reward.
• Outshine the giants: these 16 early-stage AI stocks could fund your retirement.
• Explore 26 top quantum computing companies leading the revolution in next-gen technology and shaping the future with breakthroughs in quantum algorithms, superconducting qubits, and cutting-edge research.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com